Premium
Gastrointestinal stromal tumors: Current management
Author(s) -
Pisters Peter W.T.,
Patel Shreyaskumar R.
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21460
Subject(s) - medicine , sunitinib , gist , imatinib , standard of care , stromal cell , adjuvant therapy , stromal tumor , imatinib mesylate , oncology , surgery , cancer , chemotherapy , myeloid leukemia
Abstract Herein, we review the current management of localized and advanced gastrointestinal stromal tumors (GISTs). Although surgery remains the standard of care for patients with localized GIST, adjuvant imatinib can delay recurrence in some of these patients. In patients with advanced or metastatic disease, the standard of care is imatinib and surgery of residual masses is an option. Preoperative imatinib is an emerging treatment option for patients who require cytoreductive therapy. Sunitinib is a standard second‐line therapy. J. Surg. Oncol. 2010;102:530–538. © 2010 Wiley‐Liss, Inc.